

## SYNTHETIC APPROACHES OF ISATIN DERIVATIVES AS AN ANTI-CANCER AGENT

Nehal Gandhi\*<sup>1</sup>, Priya Gandhi<sup>1</sup>, Nehal Rana<sup>1</sup>, Ayushi Hapani<sup>1</sup>, Megha Mishra<sup>2</sup>, Chetna P. Hiwase<sup>3</sup>, Shivani O. Nasare<sup>3</sup>, Kalyani D. Nirmal<sup>3</sup>, Chetana A. Lahariya<sup>3</sup>

<sup>1</sup>Department of Pharmaceutical Chemistry, S.S.Agrawal Institute of Pharmacy, Gujarat Technological University, Navsari, Gujarat, 396325, India.

<sup>2</sup>VNS Group of colleges Faculty of Pharmacy Bhopal, Madhya Pradesh, 462044, India.

<sup>3</sup>Assistant professor, Kdk college of pharmacy and research institute, Nandanvan-Nagpur, Maharashtra 440009, India.

\*Corresponding author:

Mrs. Nehal C. Gandhi

Department of Pharmaceutical Chemistry,

S.S.Agrawal Institute Of Pharmacy,

Navsari, Gujarat, India. -396325

**E-mail address:** ncgandhi82@gmail.com

ORCID No: 0009-0007-6086-7406


### Keywords

Isatin, Anti-cancer agent, Hybrid, Metal complexes, Tyrosine Kinase, Cytotoxicity

### ABSTRACT

Isatin (1H-Indole-2,3-dione) and its derivatives are an important class of Heterocyclic compounds and are majorly used as a Precursor for drug Synthesis. Since its discovery, so many research work has been done for synthesis, chemical & biological activity, and also its industrial applications. In this, we have reported several novel derivatives of N-, C-2 & C-3 substituted isatin For pharmacological activity. Here, in this study modification at C-2 and/ or C-3 carbonyl functionalities, leads to novel isatin derivatives as an anticancer activity. N- substituted novel derivatives are effective inhibitors of Carbonic anhydrase isoform IX, the form which is found to be over-expressed in a large number of solid tumors. Here also A wide range of C3-substituted isatins, like thiosemicarbazones, oxindoles, and their derivatives, imines, and hydrazones, have been synthesized. We have also summarized some recently reported biological activities exhibited by isatin derivatives, anticancer, anti-bacterial, anti-diabetic, and others. Special attention has been paid to their anti-cancer activity, and various anti-cancer targets such as histone deacetylase, carbonic anhydrase, tyrosine kinase, and tubulin against a variety of human cancer cell lines have been discussed in detail.


## Graphical Abstract



## Introduction:

Heterocyclic entities are denoted as a vital class of organic compounds with wide biological and pharmacological potency [1,2]. In view of wide-ranging biological activities, these heterocyclic analogues, either individually or as fused forms, are consistently utilized by scientists and research groups for the design of the novel candidates [3]. Among them, isatin, or (1*H*-indole-2,3-dione), has a wide spectrum of pharmacological potential and is thus appraised as a fortunate bioactive heterocyclic moiety. The isatin molecule is comprised of six- and five-membered cyclic planar rings; in contrast, the six-member ring has an aromatic character while the five-member ring possesses antiaromatic properties. Isatin was first brought to light by L. Erdman and A. Laurent in 1841 from the oxidation of indigo dye by nitric and chromic acids furnished as orange monoclinic crystals [4]. This isatin was considered a synthetic moiety for almost 140 years until it was isolated from the plants of *Isatis genus* [5], *Calanthe discolor* LINDL [6], the fruit of the cannon ball tree *Couroupita guianensis* Aubl [7], as a constituent of the secretion from the parotid gland of *Bufo* frogs [8], and as metabolic derivatives of adrenalin in humans [9]. Moreover, isatin was found to be a component of coal tar while its derivatives fall out in

variable dye, pharmaceuticals, and agriculture chemicals [7]. Nowadays, isatin has achieved a position in the design and development of medicinally active analogues because of its fortunate electronic nature. The possible substitutions for isatin hybrids are depicted in Figure 1.



**Figure 1.** Probable substitution possible on isatin nucleus.

Isatin (1*H*-indole-2,3-dione) and its derivatives represent an important class of heterocyclic compounds that can be used as precursors for drug synthesis. Since its discovery, a lot of research work has been done regarding the synthesis, chemical properties, and biological and industrial applications of isatin. In this review, we have reported several novel methods for the synthesis of *N*-C2- and C3-substituted and spiro derivatives of isatin. The isatin moiety also shows important chemical reactions such as oxidation, ring expansion, Friedel–Crafts reaction and aldol condensation. These reactions, in turn, produce several biologically viable compounds like 2-oxindoles, tryptanthrin, indirubins, and many more. We have also summarized some recently reported biological activities exhibited by isatin derivatives, like anti-cancer, anti-bacterial, anti-diabetic and others. Special attention has been paid to their anti-cancer activity, and various anti-cancer targets such as histone deacetylase, carbonic anhydrase, tyrosine kinase, and tubulin have been discussed in detail. Other applications of isatin derivatives, such as in the dye industry and in corrosion prevention, have also been discussed[9,10].

## Synthesis outlines Of Isatin Scaffolds:

### 1) Sandmeyer Synthesis

The Sandmeyer methodology is the oldest and straightforward way for the synthesis of isatin. The method involves the condensation between chloral hydrate and a primary arylamine (e.g. aniline), in the presence of hydroxylamine hydrochloride, in aqueous sodium sulfate to form an  $\alpha$ -isonitrosoacetanilide. Isolation of this intermediate and

subsequent electrophilic cyclization promoted by strong acids (e.g. sulfuric acid) furnishes isatin in >75% yield.[5]




Figure 2. Sandmeyer Synthesis.

## 2) Stolle methodology

The Stolle procedure is considered the best alternative to Sandmeyer methodology for the synthesis of both substituted and unsubstituted isatins. In this case primary or secondary arylamines are condensed with oxalyl chloride to form a chlorooxalylanilide intermediate which can then cyclize in the presence of a Lewis acid (e.g. aluminium trichloride, titanium tetrachloride, boron trifluoride, *etc.*).[5]





Figure 3. Stolle Synthesis

## Other procedures


More recent approaches to the synthesis of N-substituted isatins involves the direct oxidation of commercially available, substituted indoles or oxindoles with different oxidizing agents such as TBHP, IBX-SO<sub>3</sub>K, tBuONO etc.[11]



**Figure 4.** N- Substituted Isatin Synthesis

### C3-Substituted Isatins Synthesis:

C3-substituted isatins like thiosemicarbazone, oxindole and their derivatives, imines and hydrazones, have been synthesized. Among these derivatives, the 3-ylideneoxindole constitutes an important part of many pharmaceutical essential compounds.



**Figure 5.** C-3 Substituted Isatin Derivatives

### Reactivity

The presence of an aromatic ring, a ketone and a  $\gamma$ -lactam moiety, gives to isatin the rare potential to be used as both an electrophile and a nucleophile: indeed, it undergoes an enormous number of reactions, such as N-substitutions, electrophilic aromatic substitution at positions C-5 and C-7 of the phenyl ring, nucleophilic additions onto the C-3 carbonyl

group, chemoselective reductions, oxidations, ring-expansions and spiro-annulations. Because of this unique reactivity, isatin is considered one of the most valuable building blocks in organic synthesis.

### N-Substitution

The N-functionalization of the isatin core can be readily obtained by the deprotonation of the amino moiety, forming the corresponding sodium or potassium salt, and subsequent addition of an electrophile (e.g. alkyl or acyl halides).[11]




Figure 6. N-Substitution Reaction

On the other hand, N-arylation is usually achieved by cross-coupling reactions with aryl halides using copper or palladium catalysts.





Figure 7. N-Arylation Reaction

### Ring expansion


In the field of organic synthesis, ring expansions are considered valuable reactions since they allow the obtainment medium-size ring (7-9 atoms) which are difficult to synthesize through “classical” methods.

To date, only few articles concerning the ring expansion of isatin derivatives has been reported. The first one is an acid-catalyzed one-pot multicomponent reaction involving isatins, aminouracils, and isoxazolones to form isoxazoquinolines, important scaffolds in medicinal chemistry.



**Figure 8.** Ring Expansion Of Isatin Derivatives

In another one-pot multicomponent reaction, a unique two-carbon expansion has been achieved by reacting isatin with indene-1,3-dione and N-substituted pyridinium bromide to form dibenzo[b,d]azepin-6-ones.




**Figure 9.** One Pot multicomponent reaction

### C-2/C-3 nucleophilic addition

Isatin suffers nucleophilic addition on carbonyls at C-2 and C-3 positions.


The regioselectivity of the process strongly depends both on the substrate (properties of the substituents on the isatin core, especially those bonded to the nitrogen atom) and the reaction conditions (solvent, temperature etc.). In some cases the nucleophilic addition could be followed by secondary reactions (*e.g.* cyclization, ring expansion, ring opening *etc.*)



**Figure 10.** C-2 & C-3 Nucleophilic addition Reaction

### Oxidation


The oxidation of isatin using hydrogen peroxide or chromic anhydride yields isatoic anhydride, a compound widely used either in herbicide products and in medicinal chemistry.



**Figure 11.** Oxidation Reaction of Isatin

### Dimerization

Dimerization of isatin with KBH<sub>4</sub> in methanol yield Indirubin. This represent the indigo pigment's red component and a highly effective cytotoxic compound.



**Figure 12.** Dimerization of Isatin

### Reduction

Reduction of the non-amide carbonyl group obviously occurs to give oxindole, respectively.[12]

### Mechanism of anti-cancer action of isatin

Since it has so many different biological actions, isatin, a multifunctional indole scaffold, has attracted a lot of interest in cancer research. Isatin's potential as an anti-cancer drug was realized after it was first

shown to have broad-spectrum antibacterial and antiviral qualities. The cytotoxic effects of isatin and its derivatives on different cancer cell lines have been emphasized by a number of researches over the years [20].

Given their varied structural changes and biological activity, investigating the anti-cancer processes of isatin derivatives necessitates a multipurpose approach. Isatin produces its antineoplastic actions through numerous mechanisms, including the induction of apoptosis, cell cycle arrest, inhibition of angiogenesis, modulation of key signalling paths, inhibition of topoisomerases, and generation of ROS. This multi-targeted approach makes isatin and its scaffolds promising candidates for cancer treatment. Isatin scaffolds also induce cell cycle arrest at specific checkpoints. It prevents cancer cell proliferation. The possible mechanisms at play are broken down in detail here (Fig. 13) [21].




Fig. 13 Isatin's anti-cancer mechanism

### Isatin as antineoplastic agents:

Several isatin hybrids were produced, and their anti-cancer efficacy was evaluated by Altamimi M et al. [26]. When treated with a concentration of 10 mM as given, some of the produced compounds demonstrated excellent anti-proliferative action. The series' chemicals' inhibitory activity suggests a weak form of inhibition with the enzyme. Additionally, the action must be mostly limited to molecules with favoured groups linked to the isatin moiety. **Compounds 1, 2, 3, 4, and 5** (Fig. 14) for instance, showed exceptional efficacy against a kidney cancer cell line UO-31.

Mushtaq A and co researchers have generated isatin mono- and bis-thiosemicarbazones with good yield [27]. The spectral data of each synthesized chemical is used to describe it. Using docking

experiments, the inhibitory potential of the chosen drugs against the phosphoinositide 3-kinase (PI3K) anti-cancer protein's active sites was investigated. **Compound 6** exhibited the highest binding energy of  $-10.3 \text{ kcal mol}^{-1}$  among the produced derivatives. These results showed that mode of inhibition against PI3K signalling pathways could be employed as a preferred chemotherapeutic scaffold. In their study, Oguz A et al. [28] investigated the anti-cancer potential of newly developed lower rim-functionalized calixarenes integrated with isatin, as well as the p-position of calixarenes with 1,4-dimethylpyridinium iodine against a range of human cancer cell lines, including the PNT1A healthy epithelial cell line and the MCF-7 and MDA-MB-231 cell lines.

According to their outcomes the **compound 7** had the lowest values in MDA-MB-231 ( $3.32 \mu\text{M}$ ) and MCF-7 ( $8.83 \mu\text{M}$ ). Using confocal microscopy and flow cytometry, respectively, examinations of apoptotic activity and cell imaging were conducted. To identify chemicals in cells that have damaged DNA, the Comet assay test was employed. Comparing treated and untreated cells, it was discovered that the former had broken DNA structures and aberrant tail nuclei. **Compound 7** demonstrated a notable inhibitory impact on aromatase, as demonstrated by in vitro human aromatase enzyme inhibition profiles. As seen by its  $\text{IC}_{50}$  value of  $0.104 \pm 0.004 \mu\text{M}$ . Thus, it has been demonstrated that the novel fluorescent compounds that are the focus of this investigation exhibit both aromatase inhibitory characteristics and anti-cancer potential.


Farshid H et al. created N-alkyl-isatin-3-imino aromatic amine derivatives by alkylation and condensation processes [29]. The final compounds' cytotoxic examination showed that the type of substitution in isatin's N1 region appears to have an impact on the cytotoxic activity. Electron-withdrawing group substitutions are essential for the cytotoxic effects they provide. The MCF-7 is more vulnerable to **compounds 8 and 9**, according to the  $\text{IC}_{50}$  values of the examined compounds.

Raju and his colleagues produced a distinctive family of isatin hybrids [30]. By using the in vitro MTT test, the antineoplastic action of the synthesized scaffolds (**compound 10 and 11**) was assessed against the human breast cancer cell line (MCF-7). The most active of the examined compounds was determined to be **compound 10** (Fig. 14), which had a benzyl moiety at N4 piperazine and a promising  $\text{IC}_{50}$  ( $12.47 \text{ mM}$ ). Chalcone is the organic compound which is an  $\alpha,\beta$ -unsaturated ketone. Certain chalcones may offer medicinal promise for treating a variety of disorders, according to studies. Chalcones are aromatic ketones and enones with well-established anti-cancer properties [31]. Chalcone containing isatin nucleus was described as anti-cancer scaffolds by Cahyana AH et al. [32]. Testing of the synthesized compounds' efficacy against MCF-7 cancer cells has been done. **Compounds 12 and 13** have considerable activity against MCF-7 cancer cells when compared to another product, as indicated by the measured  $\text{IC}_{50}$  value.

Shaldama MA et al. synthesized new isatin-based sulphonamides as possible dual vascular endothelial growth factor receptor-2 (VEGFR-2) and carbonic anhydrase (CA) antagonists with antineoplastic activities [33]. Target isatins' in vitro anti-cancer effects were initially investigated against 58 tumor cell lines (NCI-USA panel). The results showed that target isatins had the greatest impact on the breast cancer subpanel. In particular, **compounds 14, 15, 16, 17, 18, 19, and 20** efficiently suppressed the development of T47D cells. Next, the isatins'  $\text{IC}_{50}$  values ( $\text{IC}_{50}$  range:  $1.83\text{--}24.13 \text{ mM}$ ) for T47D cells were ascertained. After that, the inhibitory effects of isatins 14, 16, 17, and 19 on VEGFR-2 and carbonic anhydrase were assessed. The target isatin sulphonamides were able to inhibit VEGFR-2 ( $\text{IC}_{50}$  range:  $23.10\text{--}63.40 \text{ nM}$ ) potently. However, in contrast to expectations, they were unable to antagonise the CA isoforms ( $\text{KI} > 100 \text{ mM}$ ). This could be attributed to steric hindrance by the adjacent methoxy group.

Using *Annona muricata* L leaf extract and the sol-gel method, Cahyana AH et al. [32] created Cu/NiO nanoparticles that were then utilized in the manufacture of isatin-chalcone congeners. Taking 5% mmol of these nanoparticles, the Claisen-Schmidt condensation process is used in the reflux technique to synthesize isatin based on chalcone, yielding good yields for each product. It was noted how well the six molecules worked against MCF-7 cancer cells. **Compounds 21** ( $0.00157 \mu\text{g/ml}$ ) and **22** ( $25.4521$

µg/ml) exhibit potent action against MCF-7 cancer cells in comparison to another product, as indicated by the measured IC<sub>50</sub> value.



**Fig. 14** Synthesized isatin scaffolds as anti-cancer agents (compound 1–22).

## Conclusion

As a promising new avenue for the development of anti-cancer scaffolds, isatin, and its hybrid congeners provide a variety of structural frameworks that can be optimized for increased biological activity. The present explanatory review has elucidated the many properties of isatin derivatives, demonstrating their capacity to engage with multiple biological targets, consequently impeding the growth of cancer cells, triggering programmed cell death, and preventing their spread.

Isatin-derived compounds are highly versatile due to their structural simplicity, which permits considerable chemical modification. Their overall efficacy against a variety of cancer types can be improved by these alterations, as well as their pharmacokinetic qualities and target specificity. The therapeutic potential is further increased by hybrid scaffolds, which combine isatin moieties with other bioactive substances. This often produces synergistic effects that are more effective than single-agent therapies.

Understanding the processes by which isatin derivatives exert their anti-cancer properties has advanced significantly. Among them include interactions with vital enzymes, receptors, and signalling pathways that facilitate the advancement of cancer. Furthermore, research on the structure–activity relationship (SAR) has yielded important information to design more efficient isatin-based antineoplastic scaffolds.

Despite these developments, a number of obstacles still exist. Key areas that need more research are the emergence of resistance, possible toxicity, and the requirement for targeted delivery systems. Subsequent research endeavours ought to concentrate on refining the pharmacological characteristics of isatin hybrids, thereby enhancing their specificity towards cancer cells and reducing any unfavourable impacts on healthy tissues.

In summary, isatin provides a strong platform for the creation of anti-cancer drugs, as do its hybrid scaffolds. Prolonged investigation and creativity in this area may yield new anti-cancer scaffolds that will be useful in the fight against cancer, enhance patient outcomes, and possibly even result in the treatment of other cancers. Moving these chemicals from the laboratory to the bedside will need the integration of interdisciplinary techniques, such as medicinal chemistry, molecular biology, and pharmacology.

## ACKNOWLEDGMENTS:

The authors would like to thank to S.S.Agrawal Institute for their kind support during all lab studies.

## References

- Gao F, Zhang X, Wang T, Xiao J. "Quinolone hybrids and their anti-cancer activities: an overview." *Eur MedChem.* (2019): 1(165):59-79.
- K Meenakshi, N. Gopal, M. Sarangapani. "Synthesis, characterization and antimicrobial activity of some novel Schiff and mannich bases of isatin." *Int j pharm pharm sci.* (2014): 6(6):318-322.
- Ratnamala P, Sonawane RP, Rahul R, Tripathi RR. "The chemistry and synthesis of 1H-indole-2, 3-dione and its derivatives." *International Letters of Chemistry, Physics and Astronomy* (2013): 7(1):30-36.
- Dong P, Rakesh KP, Manukumar HM, Mohammed YH, Karthik CS, Sumathi S, Mallu P, Qin HL. "Innovative nano-carriers in anticancer drug delivery-a comprehensive review." *Bioorg Chem.* (2019): 1(85):325-336.
- Pal M, Sharma NK, Priyanka, Jha KK. "Synthetic and biological multiplicity of isatin: A Review." *J Adv Sci Res.* (2011): 2(2):35-44.
- Karati D, Mahadik KR, Trivedi P, Kumar D. "Alkylating agents, the road less traversed, changing anticancer therapy." *Anticancer Agents Med Chem.* (2022): 22(8):1478-1495.
- Rakesh KP, Kumara HK, Manukumar HM, Gowda DC. "Anticancer and DNA binding studies of potential amino acids based quinazolinoneanalogs: synthesis SAR and molecular docking." *Bioorganic Chem.* (2019): 1(87): 252-264.
- Karati D, Mukherjee S, Roy S. "Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator." *Med Oncol.* (2024): 41(4):84.
- Zhao C, Rakesh KP, Mumtaz S, Moku B, Asiri AM, Marwani HM, Manukumar HM, Qin HL. "Arylnaphthalene lactone analogues: synthesis and development as excellent biological candidates for future drug discovery." *RSC Adv.* (2018): 8(17):9487-9507.
- Moku B, Ravindar L, Rakesh KP, Qin HL. "The significance of N-methylpicolinamides in the development of anticancer therapeutics: Synthesis and structure-activity relationship (SAR) studies." *Bioorg Chem.* (2019): 1(86):513-37.
- Anusha Ramgalla, Sharath Chandra R A S, Harish kumar P. "Synthesis and biological evaluation of isatin derivatives." *IJIPSR* (2015): 3(9): 1305-1318.
- Wang SM, Zha GF, Rakesh KP, Darshini N, Shubhavathi T, Vivek HK, Mallesha N, Qin HL. "Synthesis of benzo [d] thiazole-hydrazone analogues: molecular docking and SAR studies of potential H<sup>+</sup>/K<sup>+</sup> ATPase inhibitors and anti-inflammatory agents." *MedChemComm.* (2017): 8(6):1173-1189.
- Hou Y, Shang C, Wang H, Yun J. I. "satin-azole hybrids and their anticancer activities." *Arch Pharm.* (2020): 353(1):1900272.
- Kerru N, Gummidi L, Maddila S, Gangu KK, Jonnalagadda SB. "A review on recent advances in nitrogen-containing molecules and their biological applications. ." *Molecules* (2020): 25(8):1909.

15. Karati D, Mahadik KR, Trivedi P, Kumar D. “A Molecular insight into pyrazole congeners as antimicrobial.” *Anticancer Antimal Agents Med Chem.* (2022): 18(10):1044–59.
16. Maddela S, Mathew GE, Parambi DG, Aljoufi F, Mathew B. “Dual acting isatin-heterocyclic hybrids: recent highlights as promising pharmacological agents. .” *Lett Drug Des Discovery.* (2019): 16(2):220–36.
17. Zhao SQ, Xu Y, Guan J, Zhao S, Zhang GD, Xu Z. “Tetraethylene glycol tethered heteronuclear bis-isatin derivatives: design, synthesis, and in vitro anti-mycobacterial activities.” *J Heterocycl Chem.* (2018): 55(9):2172–2177.
18. Kakkar. R. “Isatin and its derivatives: a survey of recent syntheses, reactions, and applications. .” *MedChemComm* (2019): 10(3):351–368.
19. Dar OA, Lone SA, Malik MA, Aqlan FM, Wani MY, Hashmi AA, Ahmad A. “Synthesis and synergistic studies of isatin based mixed ligand complexes as potential antifungal therapeutic agents.” *Heliyon* (2019): 5(7): e02055.
20. Da Silva JF, Garden SJ, Pinto AC. “The chemistry of isatins: a review from 1975 to 1999.” *J Braz Chem Soc.* (2001): 12:273–324.
21. Abramson. HN, “Kinase inhibitors as potential agents in the treatment of multiple myeloma. .” *Oncotarget.* (2016): 7(49):81926.
22. Sandmeyer. T “Über isonitrosoacetanilide und deren Kondensation zu Isatinen. .” *Helvetica Chimica Acta.* (1919): 2(1):234–42.
23. Zebbiche Z, Tekin S, Küçükbay H, Yüksel F, Boumoud B. “Synthesis and anticancer properties of novel hydrazone derivatives incorporating pyridine and isatin moieties. .” *Arch Pharm.* (2021): 354(5):2000377.
24. Ferraz de Paiva RE, Vieira EG, Rodrigues da Silva D, Wegermann CA, Costa Ferreira AM. “Anticancer compounds based on isatin-derivatives: strategies to ameliorate selectivity and efficiency. .” *Front Mol Biosci* (2021): 7:627272.
25. Ding Z, Zhou M, Zeng C. . “Recent advances in isatin hybrids as potential anticancer agents.” *Arch Pharm.* (2020): 353(3):1900367.
26. Meunier B., 2. “Hybrid molecules with a dual mode of action: dream or reality? .” *Acc Chem Res.* (2008): 41(1):69–77.
27. Mishra S, Singh P. . “Hybrid molecules: the privileged scaffolds for various pharmaceuticals.” *Eur J Med Chem.* (2016): 29(124):500–36.
28. Wang M, Rakesh KP, Leng J, Fang WY, Ravindar L, Gowda DC, Qin HL. “ Amino acids/peptides conjugated heterocycles: a tool for the recent development of novel therapeutic agents.” *Bioorg Chem.* (2018): 1(76):113–129.
29. Altamimi M, Syed SA, Tuzun B, Alhazani MR, Alnemer O, Bari A. J. “Synthesis biological evaluation and molecular docking of isatin hybrids as anti-cancer and anti-microbial agents.” *Enzyme Inhib Med Chem.* (2024): 39(1):2288548.
30. Mushtaq A, Asif R, Humayun WA, Naseer MM. “Novel isatin–triazole based thiosemicarbazones as potential anticancer agents: synthesis, DFT and molecular docking studies. .” *RSC Adv.* (2024): 14(20):14051–67.

31. Oguz A, Saglik BN, Oguz M, Ozturk B, Yilmaz M. “Novel mitochondrial and DNA damaging fluorescent Calix [4] arenes bearing isatin groups as aromatase inhibitors: Design, synthesis and anticancer activity. .” *Bioorg Med Chem.* (2024): 15(98): 117586.
32. Hassanzadeh F, Hejazi SH, Jafari E, Sadeghi-aliabadi H. “Molecular docking and synthesis of N-alkyl-isatin-3-imino aromatic amine derivatives and their antileishmanial and cytotoxic activities.” *Res Pharmaceut Sci.* (2024): 19(2):238–50.
33. Raju R, Chidambaram K, Chandrasekaran B, Bayan MF, Maity TK, Alkahtani AM, Chandramoorthy HC. “Synthesis, pharmacological evaluation, and molecular modeling studies of novel isatin hybrids as potential anticancer agents.” *J Saudi Chem Soc.* (2023): 27(2): 1.
34. Repanas A, Katsori AM, Hadjipavlou-Litina D. “Chalcones in cancer: understanding their role in terms of QSAR II part. .” *Mini-Reviews Med Chem.* (2013): 13(7):952–70.
35. Cahyana AH, Saputri YL, Yunarti RT, Woo SK. “Eco-friendly Cu/NiO nanoparticle synthesis: catalytic potential in isatin-based chalcone synthesis for anticancer activity.” *MethodsX* (2023): 1(11): 102471.
36. MRP Rao, S Taktode, SS Shivpuje, S Jagtap. Optimization of Transmucosal Buccal Delivery of Losartan Potassium using Factorial Design. *Indian Journal of Pharmaceutical Education and Research*, 2016; 50(2): S132-S139.
37. N Patre, S Patwekar, S Dhage, S Shivpuje. Formulation & Evaluation Of Piroxicam Bionanocomposite For Enhancement of Bioavailability. *European Journal of Molecular & Clinical Medicine*, 2020; 7(11): 9362-9376.
38. SJ Wadher, SL Patwekar, SS Shivpuje, SS Khandre, SS Lamture. Stability Indicating Assay Methods for Simultaneous Estimation of Amoxicillin Trihydrate And Cloxacillin Sodium in Combined Capsule Dosage Form by UV-Spectrophotometric Method. *European Journal of Biomedical and Pharmaceutical sciences*, 2017; 4(10): 858-864.
39. Santosh A. Payghan Shivraj S. Shivpuje Shailesh L. Patwekar, Karna B. Khavane, Padmavati R. Chainpure. A Review on Different Preparation Method Used For Development of Curcumin Nanoparticles. *International Journal of Creative Research Thoughts*, 2021;9(1):4088-4101.
40. Zeba Ashfaq Sheikh P. R. Chainpure, S. L. Patwekar, S. S. Shivpuje. Formulation and evaluation of Garciniacambogia and Commiphoramukul Herbal tablets used for AntiObesity. *International Journal of Engineering, Science and Mathematics*, 2019; 8(4): 180-195.
41. Pravin P Karle, Shashikant C Dhawale, Vijay V Navghare, Shivraj S Shivpuje. Optimization of extraction conditions and evaluation of Manilkara zapota (L.) P. Royen fruit peel extract for in vitro  $\alpha$ -glucosidase enzyme inhibition and free radical scavenging potential. *Future Journal of Pharmaceutical Sciences*, 2021; 7(1):1-10.
42. Sheetal Rathod P. R. Chainpure, S. L. Patwekar, S. S. Shivpuje. A Study Of Carica Papaya Concerning It's Ancient And Traditional Uses - Recent Advances And Modern Applications For Improving The Milk Secretion In Lactating Womens. *International Journal of Research*, 2019;8(2):1851-1861.

43. Shivraj S. Shivpuje Shailesh J. Wadher, Bhagwan B. Supekar. Development And Validation Of New Ft-Ir Spectrophotometric Method For Simultaneous Estimation Of Ambroxol Hydrochloride And Cetirizine Hydrochloride In Combined Pharmaceutical. *International Research Journal of Pharmacy*, 2019; 10(3):110-114.
44. Shivraj S. Shivpuje, Shailesh J. Wadher, Bhagwan B. Supekar. Simultaneous Estimation of Ambroxol Hydrochloride and Cetirizine Hydrochloride in Combined Solid Tablet Formulations by HPTLC- Densitometric Method. *Asian Journal of Biochemical and Pharmaceutical Research*, 2019; 9(1):1-10.
45. JW Sailesh, SS Shivraj, SI Liyakat. Development and Validation of Stability Indicating RP-HPLC Method for the Estimation of Simvastatin in Bulk and Tablet Dosage form. *Research Journal of Pharmacy and Technology*, 2018; 11(4): 1553-1558.
46. Patil S. S. Shivpuje Shivraj S. Patre Narendra G. Development and Validation Of Stability Indicating HPTLC Method For Determination of Nisoldipine (Niso) In Tablet Dosage Form. *European Journal of Biomedical and Pharmaceutical sciences*, 2017; 4(12):462468.
47. W Shailesh, K Tukaram, S Shivraj, L Sima, K Supriya. Development and Validation of Stability Indicating UV Spectrophotometric Method for Simultaneous Estimation of Amoxicillin Trihydrate and Metronidazole In Bulk And In-House Tablet. *World Journal of Pharmaceutical and Medical Research*, 2017;3(8):312-318.
48. J Wadher Shailesh, M Kalyankar Tukaram, S Shivpuje Shivraj. Development and Validation of Stability Indicating Assay Method for Simultaneous Estimation of Amoxicillin Trihydrate and Cloxacillin Sodium In Pharmaceutical Dosage Form By Using RP-HPLC. *World Journal of Pharmaceutical Research*, 2017; 10(6):1002-1006.
49. Shital S. Sangale, Priyanka S. Kale, Rachana B. Lamkane, Ganga S. Gore, Priyanka B. Parekar, Shivraj S. Shivpuje (2023). Synthesis of Novel Isoxazole Derivatives as Analgesic Agents by Using Eddy's Hot Plate Method. *South Asian Res J Pharm Sci*, 5(1): 18-27.
50. Priyanka B. Parekar, Shivraj S. Shivpuje, Vijay V. Navghare, Manasi M. Savale, Vijaya B. Surwase, Priti S. Mane- Kolpe, Priyanak S. Kale. Polyherbal Gel Development And Evaluation For Antifungal Activity, *European Journal of Molecular & Clinical Medicine*. 2022; 9(03): 5409-5418.
51. Jain AA, Mane-Kolpe PD, Parekar PB, Todkari AV, Sul KT, Shivpuje SS. Brief review on Total Quality Management in Pharmaceutical Industries, *International Journal of Pharmaceutical Research and Applications*. 2022; 7(05):1030-1036.
52. Sumaiyya. K. Attar, Pooja P. Dhanawade, Sonali S. Gurav , Prerna H. Sidwadkar , Priyanka B. Parekar, Shivraj S. Shivpuje. Development and Validation of UV Visible Spectrophotometric Method for Estimation of Fexofenadine Hydrochloride in Bulk and Formulation, *GIS SCIENCE JOURNAL*. 2022; 9(11): 936-944.
53. Sumayya Kasim Atar, Priyadarshini Ravindra Kamble, Sonali Sharad Gurav, Pooja Pandit Dhanawade, Priyanka Bhanudas Parekar, Shivraj Sangapa Shivpuje. Phytochemical Screening, Physicochemical Analysis of Starch from *Colocasia Esculenta*, *NeuroQuantology*, 2022; 20(20): 903-917.

54. Priti D.Mane-Kolpe, Alfa A. Jain, Tai P. Yele, Reshma B. Devkate, Priyanka B. Parekar, Komal T. Sul, Shivraj S. Shivpuje. A Systematic Review on Effects of Chloroquine as a Antiviral against Covid-19, *International Journal of Innovative Science and Research Technology*, 2022;7(11): 989-995.
55. Dr. Rohit Jadhav, Prof. Abhay D. Kale, Dr. Hitesh Vishwanath Shahare, Dr. Ramesh Ingole, Dr Shailesh Patwekar, Dr S J Wadher, Shivraj Shivpuje. Molecular Docking Studies and Synthesis of Novel 3-(3- hydroxypropyl)-(nitrophenyl)[1,3] thiazolo [4,5-d] pyrimidin2(3H)-one as potent inhibitors of P. Aeruginosa of S. Aureus, *Eur. Chem. Bull.* 2023; 12(12): 505-515.
56. Priyanka B. Parekar, Savita D. Sonwane, Vaibhav N. Dhakane, Rasika N. Tilekar, Neelam S. Bhagdevani, Sachin M. Jadhav, Shivraj S. Shivpuje, Synthesis and Biological Evaluation of Novel 1,3,4-Oxadiazole Derivatives as Antimicrobial Agents, *Journal of Cardiovascular Disease Research*, 2023; 14(8):611-624.
57. Kavita R. Mane, Prachi A. Ghadage, Aishwarya S. Shilamkar, Vaishnavi A. Pawar, Sakshi B. Taware, Priyanka B. Parekar, Shivraj S. Shivpuje. Phytochemical Screening, Extraction and In-vivo study of Immunomodulation effect of *Withania somnifera*, *Momordicadioica* and *Annonasquamosa* leaves. *Journal of Cardiovascular Disease Research*, 2023; 14(9): 231-241.
58. Harshada S. Deshmukh, Vishal B. Babar, Prajkta S. Jagtap, Rupendra V. Doshi, Shivarti V. Deokate, Ashwini V. Todkari, Amrata S. Mantri, Priyanka B. Parekar, Shivraj Shivpuje (2024). A Comprehensive Review Article on Herbal Cosmetics. *South Asian Res J Pharm Sci*, 6(3): 50-68.